There’s no right answer…Jolie’s essay reflects the dilemma of any person making a medical choice based on their circumstances, values, genetic test results and what information they’ve been given or otherwise found and interpreted.
The residents hadn’t a clue what was happening to their water. Fagin, an environmental journalist, wades through a half century of dumping, denial, Greenpeace efforts to expose the situation, local citizens’ mixed responses…
the words we use matter enormously, not just in clinical outcomes, but in how people with cancer feel about the decisions they’ve made, years later.
This slim 1956 novel by Mark Harris, oddly elegant in its tenderness and guyish language, resonates today.
I’m optimistic, because it looks as though, in my lifetime, BC treatment will be tailored to each patient. There’ll be less surgery and better drugs.
Yesterday a video came my way on Facebook. It’s a stand-up piece by Anthony Griffith, who tells what it was like working as a comedian when his 2-year old daughter had recurrent cancer and died….This 9 minute clip packs sadness and pain:
I hope this week’s headlines and editorials don’t add to the blurriness of the public’s perception of cancer screening – that people might begin to think it’s a bad thing all around. The details matter….screening if it’s done right can save lives and dollars. That’s because for most tumor types, treating advanced, metastatic disease is costlier than treatment of early-stage, curable tumors.
A seemingly slight adjustment in a statistic, for teaching purposes, can significantly change a test’s calculated value….
A tanning salon – a business that causes melanoma and other skin cancers – is promoting a walk of bikini-wearing women in summer sun to break an amusing world’s record. This parade will …
This kind of paternalism, when a doctor assesses the risks and benefits, and spares the patient’s “knowing” seems anachronistic. But it may, still, be what many people are looking for when and if they get a serious illness. Not everyone wants a “tell me everything” kind of physician.
This news reminds us an aspect of cancer treatment some of us would rather put out of our heads….all cancer patients should take careful notes on their planned treatments and ask their doctors about the long-term consequences of therapy.
My opinion is not quite formed on this new antibody. The FDA’s decision was based on results of one trial of 808 patients, half of whom didn’t get the experimental drug…
Last October, I met Suzanne at a conference. She seemed familiar; that was because I’d read about her life with metastatic breast cancer (MBC) a few months back…
The new agent is a hybrid of an old monoclonal antibody, Herceptin, that’s chemically attached to DM1, a traditional kind of chemotherapy. The preliminary results of this randomized trial are encouraging. …It’s hard to know how this promising, likely expensive, intravenous drug will fit in with others for patients with Her2+ breast cancer.
Last week the National Breast Cancer Coalition (NBCC) held its annual summit. The meeting drew over 600 women to its opening rally in a Crystal City ballroom on Saturday, along with students who participated in sessions for Emerging Leaders, and a few men who joined in lectures and panels, and lobbied on Tuesday on Capitol […]
The 10 molecular BC categories bear prognostic (survival) information and, based on their distinct mutations and gene expression patterns, potential targets for novel drugs….I wonder if, in a few years, some breast cancers might be treated without surgery.
If a drug helps, keep it going; if it hurts, stop. There are so many algorithms in medicine, and molecular tools, but maybe the bottom line is how the, one, your patient is doing.
Few forms of invasive breast cancer warrant no treatment unless the patient is so old that she is likely to die first of another condition, or the patient prefers to die of the disease….“Mammograms Spot Cancers That May Not Be Dangerous,” said WebMD, yesterday. This is feel-good news, and largely wishful.
The new findings have no bearing on whether or not cancer screening is cost-effective or life-saving. What the study does suggest is that med school math requirements should be upped and rigorous, counter to the trend
My take is that periodic colonoscopy has the potential to halve the number of deaths from colon cancer in the general population…As to how colonoscopy relates to fecal blood testing as a screening method at the population level, and the optimal start and frequency of either test, those remain uncertain.